Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.54 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.54 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950954 | 0.88 | GMNN (0.66) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL9960429 | 0.83 | TSHR (0.46) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL846137 | 0.81 | CYP4F2 (0.57) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL22334798 | 0.81 | CYP4F2 (0.65) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL19643200 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2CYP2D6GMNNALDH1A1LMNA | |
| SCHEMBL765000 | 0.79 | CYP4F2 (0.62) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL765847 | 0.79 | CYP4F2 (0.62) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL10289874 | 0.79 | CYP4F2 (0.62) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 | |
| SCHEMBL11718440 | 0.78 | SMN1; SMN2 (0.60) | CYP4F2CYP4A11ALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL14947362 | 0.78 | SMN1; SMN2 (0.51) | CYP4F2CYP4A11ALOX5CYP4Z1CYP4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468716-B1 | Process for producing bendamustine alkyl esters, bendamustine and derivatives of same | HERAEUS DEUTSCHLAND GMBH & CO KG (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-8481751-B2 | Process for the production of bendamustine alkyl ester, bendamustine, and derivatives thereof | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120165543-A1 | PROCESS FOR THE PRODUCTION OF BENDAMUSTINE ALKYL ESTER, BENDAMUSTINE, AND DERIVATIVES THEREOF | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2012-06-28 | — | — | US | disclosed |
| EP-2468716-A1 | Process for producing bendamustine alkyl esters, bendamustine and derivatives of same | Heraeus Precious Metals GmbH & Co. KG (DE) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165543-A1 | PROCESS FOR THE PRODUCTION OF BENDAMUSTINE ALKYL ESTER, BENDAMUSTINE, AND DERIVATIVES THEREOF | OTC, OAT, BCKDK | CYP4F2 396/4885CYP4A11 2207/4885ALOX5 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.